SeaStar Medical Q2 EPS Forecast Decreased by Zacks Research

SeaStar Medical Holding Corporation (NASDAQ:ICU) – Analysts at Zacks Research reduced their Q2 2026 earnings per share estimates for shares of SeaStar Medical in a report released on Monday, May 18th. Zacks Research analyst D. Bautz now anticipates that the company will earn ($0.91) per share for the quarter, down from their previous estimate of ($0.71). The consensus estimate for SeaStar Medical’s current full-year earnings is ($3.58) per share. Zacks Research also issued estimates for SeaStar Medical’s Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.58) EPS, FY2027 earnings at ($2.09) EPS and FY2028 earnings at ($0.76) EPS.

A number of other research firms have also recently issued reports on ICU. Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a research note on Tuesday, April 21st. Wall Street Zen cut SeaStar Medical from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Maxim Group set a $8.00 target price on SeaStar Medical and gave the company a “buy” rating in a research note on Thursday, May 14th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, SeaStar Medical presently has an average rating of “Hold” and a consensus price target of $8.00.

SeaStar Medical Stock Performance

ICU stock opened at $3.75 on Monday. The firm has a market cap of $15 million, a P/E ratio of -0.78 and a beta of -1.04. SeaStar Medical has a 12-month low of $2.07 and a 12-month high of $13.10. The stock’s 50 day simple moving average is $3.75 and its 200 day simple moving average is $3.21.

SeaStar Medical (NASDAQ:ICU) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.44 million. SeaStar Medical had a negative net margin of 828.62% and a negative return on equity of 146.29%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ICU. XTX Topco Ltd increased its holdings in shares of SeaStar Medical by 395.4% during the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after purchasing an additional 48,674 shares during the period. Jane Street Group LLC acquired a new position in shares of SeaStar Medical during the fourth quarter valued at $30,000. Finally, Millennium Management LLC acquired a new position in shares of SeaStar Medical during the third quarter valued at $102,000. 1.69% of the stock is owned by institutional investors and hedge funds.

SeaStar Medical Company Profile

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.